Elanco Animal Health (ELAN) is set to see "accelerating" earnings before interest, taxes, depreciation, and amortization growth in 2026 even with "modest" share capture and low-single-digit same-store EBITDA growth and a "bleak" Zenrelia outlook, UBS said in a note Monday.
The investment firm said that "excessive focus" on the performance of Zenrelia overlooks the broader long-term growth drivers, including expansion into new verticals and easing selling, general, and administrative, or SG&A expenses. Zenrelia is a treatment indicated for canine allergic itch and inflammation.
UBS analysts said they believe there's a "strong potential for EBITDA recovery," versus "low downside risk," which presents a "compelling 3:1 skew, highlighting an attractive long opportunity at depressed levels."
The firm noted that the potential for EBITDA acceleration is supported by long-term gross profit levers and rapid deleveraging.
UBS initiated coverage of Elanco with a buy rating and a $18 price target.
Shares of Elanco were up 3.4% in recent trading.
Price: 12.91, Change: +0.41, Percent Change: +3.28
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.